Literature DB >> 22696229

EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival.

Michiel Smits1, Sjoerd van Rijn, Esther Hulleman, Dennis Biesmans, Dannis G van Vuurden, Marcel Kool, Christine Haberler, Eleonora Aronica, W Peter Vandertop, David P Noske, Thomas Würdinger.   

Abstract

PURPOSE: Medulloblastoma is the most common malignant brain tumor in children. Despite recent improvements, the molecular mechanisms driving medulloblastoma are not fully understood and further elucidation could provide cues to improve outcome prediction and therapeutic approaches. EXPERIMENTAL
DESIGN: Here, we conducted a meta-analysis of mouse and human medulloblastoma gene expression data sets, to identify potential medulloblastoma tumor suppressor genes.
RESULTS: We identified DAB2IP, a member of the RAS-GTPase-activating protein family (RAS GAP), and showed that DAB2IP expression is repressed in medulloblastoma by EZH2-induced trimethylation. Moreover, we observed that reduced DAB2IP expression correlates significantly with a poor overall survival of patients with medulloblastoma, independent of metastatic stage. Finally, we showed that ectopic DAB2IP expression enhances stress-induced apoptosis in medulloblastoma cells and that reduced expression of DAB2IP in medulloblastoma cells conveys resistance to irradiation-induced cell death.
CONCLUSION: These results suggest that repression of DAB2IP may at least partly protect medulloblastoma cells from apoptotic cell death. Moreover, DAB2IP may represent a molecular marker to distinguish patients with medulloblastoma at high risk from those with a longer survival prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22696229     DOI: 10.1158/1078-0432.CCR-12-0399

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  EZH2, Proliferation Rate, and Aggressive Tumor Subtypes in Cutaneous Basal Cell Carcinoma.

Authors:  Rajesh C Rao; May P Chan; Christopher A Andrews; Alon Kahana
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

Review 2.  Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer.

Authors:  Arianna Bellazzo; Giulio Di Minin; Licio Collavin
Journal:  Cell Death Differ       Date:  2016-11-18       Impact factor: 15.828

3.  Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.

Authors:  Irene Marchesi; Luigi Bagella
Journal:  World J Clin Oncol       Date:  2016-04-10

4.  Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.

Authors:  J Zhou; J Luo; K Wu; E-J Yun; P Kapur; R-C Pong; Y Du; B Wang; C Authement; E Hernandez; J Yang; G Xiao; T-L Cha; H-C Wu; D Wu; V Margulis; Y Lotan; J Brugarolas; D He; J-T Hsieh
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

Review 5.  Epigenetic regulation in medulloblastoma.

Authors:  Jiaqing Yi; Jiang Wu
Journal:  Mol Cell Neurosci       Date:  2017-12-18       Impact factor: 4.314

Review 6.  Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.

Authors:  Anshika Bakshi; Sandeep C Chaudhary; Mehtab Rana; Craig A Elmets; Mohammad Athar
Journal:  Mol Carcinog       Date:  2017-08-22       Impact factor: 4.784

7.  SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development.

Authors:  X Shi; Q Wang; J Gu; Z Xuan; J I Wu
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

8.  EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.

Authors:  Xingyue Zong; Weini Wang; Ali Ozes; Fang Fang; George E Sandusky; Kenneth P Nephew
Journal:  Cancer Res       Date:  2020-08-19       Impact factor: 12.701

9.  Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival.

Authors:  Yeong-Chin Jou; Yuh-Shyan Tsai; Syue-Yi Chen; Hsiao-Yen Hsieh; Hsin-Tzu Tsai; Tzong-Shin Tzai
Journal:  Virchows Arch       Date:  2016-03-22       Impact factor: 4.064

10.  The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer.

Authors:  Zhongwei Li; Pingfu Hou; Dongmei Fan; Meichen Dong; Musong Ma; Hongyuan Li; Ruosi Yao; Yuxin Li; Guannan Wang; Pengyu Geng; Adhanom Mihretab; Dongxu Liu; Yu Zhang; Baiqu Huang; Jun Lu
Journal:  Cell Death Differ       Date:  2016-10-07       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.